Financials

v3.4.0.3
Consolidated Condensed Balance Sheets - USD ($)
Mar. 31, 2016
Dec. 31, 2015
Current assets:    
Cash and cash equivalents $ 10,594,828 $ 5,918,424
Short-term investments 7,382,344 13,701,273
Accounts receivable 1,192,476 631,084
Other current assets 500,108 442,642
Total current assets 19,669,756 20,693,423
Equipment, net 66,293 122,958
Restricted cash 40,602 37,663
Other long-term assets 26,581 26,560
Total assets 19,803,232 20,880,604
Current liabilities:    
Accounts payable 246,492 197,134
Accrued expenses 1,866,730 1,584,826
Deferred revenue 105,216 11,892
Accrued warrant liability 2,636,187 4,048,900
Total current liabilities 4,854,625 5,842,752
Commitments and contingencies 0 0
Total liabilities 4,854,625 5,842,752
Stockholders’ equity:    
Preferred stock, $.005 par value; 10,000,000 shares authorized, 0 shares issued and outstanding as of March 31, 2016 and December 31, 2015 0 0
Common stock, $.005 par value; 160,000,000 shares authorized, 10,987,166 shares issued and outstanding as of March 31, 2016 and December 31, 2015 54,932 54,932
Additional paid-in capital 158,771,586 158,764,985
Other comprehensive loss (407,896) (408,051)
Accumulated deficit (148,646,767) (147,978,831)
Treasury stock, at cost; 0 and 158,900 shares as of March 31, 2016 and December 31, 2015, respectively 0 (544,853)
Total Cleveland BioLabs, Inc. stockholders’ equity 9,771,855 9,888,182
Noncontrolling interest in stockholders’ equity 5,176,752 5,149,670
Total stockholders’ equity 14,948,607 15,037,852
Total liabilities and stockholders’ equity $ 19,803,232 $ 20,880,604
v3.4.0.3
Consolidated Condensed Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Revenues:    
Grants and contracts $ 812,500 $ 607,329
Operating expenses:    
Research and development 1,941,240 1,610,970
General and administrative 1,183,566 2,307,871
Total operating expenses 3,124,806 3,918,841
Loss from operations (2,312,306) (3,311,512)
Other income (expense):    
Interest and other income (expense) 181,765 (46,394)
Foreign exchange gain (loss) 47,086 (43,735)
Change in value of warrant liability 1,412,713 (49,358)
Equity in loss of Incuron, LLC 0 (247,566)
Total other income (expense) 1,641,564 (387,053)
Net loss (670,742) (3,698,565)
Net loss attributable to noncontrolling interests 2,806 48,243
Net loss attributable to Cleveland BioLabs, Inc. $ (667,936) $ (3,650,322)
Net loss attributable to common stockholders per share of common stock, basic and diluted (in dollars per share) $ (0.06) $ (1.14)
Weighted average number of shares used in calculating net loss per share, basic and diluted (shares) 10,987,166 3,206,249
v3.4.0.3
Consolidated Condensed Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Cash flows from operating activities:    
Net income (loss) $ (670,742) $ (3,698,565)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 26,617 65,639
Non-cash investment income (9,410) 0
Noncash compensation 11,457 33,640
Warrant issuance costs 0 617,776
Equity in loss of Incuron, LLC 0 247,566
Change in value of warrant liability (1,412,713) 49,358
Changes in operating assets and liabilities:    
Accounts receivable and other current assets (554,013) (113,235)
Other long-term assets 0 3,986
Accounts payable and accrued expenses 268,358 311,922
Deferred revenue 83,703 254,363
Net cash used in operating activities (2,256,743) (2,227,550)
Cash flows from investing activities:    
Purchase of short-term investments 0 (723,661)
Sale of short-term investments 6,335,062 0
Purchase of equipment 0 (3,756)
Proceeds from sale of equipment 15,327 0
Decrease in restricted cash 0 770,609
Net cash provided by investing activities 6,350,389 43,192
Cash flows from financing activities:    
Issuance of common stock, net of offering costs 0 3,501,457
Repayment of long-term debt and capital leases 0 (189,580)
Net proceeds from sale of treasury stock 539,998 0
Net cash provided by financing activities 539,998 3,311,877
Effect of exchange rate change on cash and equivalents 42,760 24,528
Increase (decrease) in cash and cash equivalents 4,676,404 1,152,047
Cash and cash equivalents at beginning of period 5,918,424 3,103,969
Cash and cash equivalents at end of period 10,594,828 4,256,016
Supplemental disclosure of cash flow information:    
Cash paid during the period for interest $ 0 $ 47,782
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue